Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...

A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.

Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...

A key question for ESO-T01 and other in vivo candidates will be the durability of their cancer eradication. While the ...

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

SMART control of CAR T cells is advancing cancer immunotherapy by improving precision, safety, and adaptability. Why Smart ...

Scientists have developed a method to reprogram cancer-fighting immune cells directly inside the body, potentially ...

A cell-based immunotherapy designed to treat rare and aggressive types of blood cancer has been granted Breakthrough Therapy ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...